Pharsight

1. List of Vyxeos drug patents

Application	Filing Date	Opposition Party	Legal Status
EP17200498A	2022-10-12	Generics [UK] Limited	Granted and Under Opposition
EP17200498A	2022-10-11	STADA Arzneimittel AG	Granted and Under Opposition
EP17200498A	2022-10-11	SANDOZ AG	Granted and Under Opposition
EP12841616A	2020-04-24	D Young & Co LLP	Granted and Under Opposition
EP12841616A	2020-04-23	SANDOZ AG	Granted and Under Opposition
EP08730048A	2018-08-15	Teva Pharmaceutical Industries Ltd	Revoked
EP08730048A	2018-08-15	Generics (U.K.) Limited	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US9271931	October, 2012	Decision	Paul Tardi et al
US8518437	December, 2010	Decision	Paul Tardi et al

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431806	CELATOR PHARMS	Liposomal formulations of anthracycline agents and cytidine analogs	Apr, 2025 (1 year, 10 months from now)
US8518437	CELATOR PHARMS	Lipid carrier compositions with enhanced blood stability	Jun, 2026 (3 years from now)
US9271931	CELATOR PHARMS	Compositions for delivery of drug combinations	Jan, 2027 (3 years from now)
US7850990	CELATOR PHARMS	Compositions for delivery of drug combinations	Jan, 2027 (3 years from now)
US8022279	CELATOR PHARMS	Liposomal formulations of anthracycline agents and cytidine analogs	Sep, 2027 (4 years from now)
US8092828	CELATOR PHARMS	Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders	Apr, 2029 (5 years from now)
US10028912	CELATOR PHARMS	Method of lyophilizing liposomes	Oct, 2032 (9 years from now)
US10835492	CELATOR PHARMS	Method of lyophilizing liposomes	Oct, 2032 (9 years from now)
US10166184	CELATOR PHARMS	Method of lyophilizing liposomes	Oct, 2032 (9 years from now)

Do you want to check out VYXEOS patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 3, 2024
New Patient Population (NPP)	Mar 30, 2024

Market Authorisation Date: 03 August, 2017

Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older; Method of ad...

Dosage: POWDER;INTRAVENOUS